In 2014, the Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) from schedule III to schedule II. The study objective was to determine if the rescheduling of HCPs influenced the analgesic prescribing choice that Texas Advanced Practice Providers (APPs) (i.e., nurse practitioners [NPs] and physician assistants [PAs]) provide to patients who are in need of pain management. A cross-sectional survey design was employed. The self-administered online questionnaire for the APPs was developed utilizing the Theory of Reasoned Action and included questions about pain management strategies. Data analyses involved measurement of descriptive statistics related to questions about planned treatment alternatives or substitutions for HCPs and, determination of inter-item reliability and correlations. An a priori significance level of P < 0.05 was used for all statistical tests. SAS® version 9.4 was used for statistical analyses. Responses from 1,059 APPs were collected with a 17.6% response rate. The mean age of respondents in this study was 47±12 years with 74% females. Most (71%) of APPs believed that rescheduling HCPs has altered their pain management care. With respect to non-cancer pain management (NCPM), (20.62%) of the APPs who reported using the PDMP reported prescribing schedule II opioids for less than 20% of their patients. Over half (54%) stated that they intended to prescribe acetaminophen with codeine after rescheduling of HCPs. Most (73%) of the prescribers reported that they were very likely/quite likely to prescribe tramadol or tramadol/acetaminophen combination products to treat acute non cancer pain. Advanced Practice Providers (APPs) are influenced by the change in policy in Texas due to lack of schedule II prescriptive authority and believe that the rescheduling has resulted in an alteration in the pain management care of patients. Further research is required to assess if rescheduling has contributed to reduction in drug misuse and diversion.